Tokuichiro Utsunomiya

Minophagen Pharmaceutical Co., Ltd. will celebrate its 85th anniversary in June 2023. We would like to take this opportunity to express our sincere gratitude to all of you for your patronage and support. Based on our "Corporate Philosophy", we aim to be a development-oriented global niche pharmaceutical company that constantly strives for innovation and provides creative, high-quality products that respond to changing times.

In Japan, sales of the therapeutic agent for Cutaneous T-cell Lymphoma, Targretin®Capsules 75mg (generic name: bexarotene), which was launched in June 2016, have been solid, and we have been aiming to expand the indication for adult patients suffering from T-cell leukemia (ATL), with a clinical trial for this having been completed, and we plan to apply for approval by the end of this year. In addition, an application for clinical trials in China has been accepted by the authorities, and preparations are underway with local partner companies. In addition, with the support of partners in Asia and the CIS countries, we have obtained approval from the authorities in Laos, Cambodia, and Azerbaijan, and have begun exporting "Strong Neo-Minophagen C" (hereinafter referred to as SNMC).

On the other hand, in the Chinese market, which is our main market, the business environment has changed significantly due to the spread of the regional centralized purchasing system throughout the country because of the medical cost control measures for our main products SNMC and Glycyron Tablets. Affected by this impact, we have fundamentally revised our earnings structure of relying on exports to China. By strengthening new and existing partnerships in Japan and overseas, we will promote the introduction of orphan drugs in the domestic market following Bexarotene, and strengthen partnerships in the ASEAN region by rebuilding and expanding our business foundation as a global niche pharmaceutical company.

We will contribute to the health and welfare of people all over the world by seeking to improve benefits for patients and families, complying with laws and regulations, and continuing to provide safe, high-quality pharmaceutical products. We respectfully request your continued support.

July, 2023
Tokuichiro Utsunomiya, Ph.D.
CEO & President

Page Top